On June 17, the House of Representatives Appropriations Committee released a bill that outlines the funding for the Food and Drug Administration (FDA) for 2016. But the bill has an unusual caveat: if it passes as it currently stands, it would bar the agency from spending any money to assess research or clinical applications for products that manipulate the human genome. It would also require the agency to set up a committee to review a forthcoming report that considers the ethics of editing human embryos.
Lawmakers Move To Ban Funding For Human Embryo Editing
